Lv11
66 积分 2025-01-21 加入
Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study
2小时前
已完结
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
1个月前
已完结
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO ‐4 Trial
1个月前
已完结
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
2个月前
已完结
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
2个月前
已完结
Two decades of PARP inhibitor synthetic lethality in cancer
3个月前
已完结
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
4个月前
已完结
The emerging safety profile of JAK inhibitors in rheumatic disease
4个月前
已完结
Diagnosis and Treatment of Acute Appendicitis
4个月前
已完结
Implementation of Treat‐to‐Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial
6个月前
已完结
皖公网安备34019202002308
